Financial reports
ARS
2023 FY
Annual report to shareholders
23 Apr 24
10-K
2023 FY
Annual report
22 Feb 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
ARS
2022 FY
Annual report to shareholders
30 May 23
10-Q
2023 Q1
Quarterly report
11 May 23
10-K
2022 FY
Annual report
23 Feb 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
Current reports
8-K
AVITA Medical Updates Expected First Quarter 2024 Revenue
11 Apr 24
8-K
AVITA Medical Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance
22 Feb 24
8-K
AVITA Medical Announces Preliminary 2023 Financial Highlights, Provides 2024 Financial Guidance and Business Update
10 Jan 24
8-K
AVITA Medical Reports Third Quarter Financial Results with 51% Revenue Growth over the Same Period the Prior Year
9 Nov 23
8-K
Departure of Directors or Certain Officers
23 Oct 23
8-K
Preliminary commercial revenue of $13.5 million for the third quarter 2023; full year 2023 guidance confirmed
18 Oct 23
8-K
Other Events
2 Oct 23
8-K
AVITA Medical Reports Second Quarter Financial Results
10 Aug 23
8-K
Regulation FD Disclosure
26 Jun 23
8-K
AVITA Medical Announces Appointment of David O’Toole as Chief Financial Officer
15 Jun 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
18 Oct 23
S-8
Registration of securities for employees
30 Jun 23
424B2
Prospectus for primary offering
25 Apr 23
S-3
Shelf registration
14 Apr 23
424B5
Prospectus supplement for primary offering
26 Feb 21
424B5
Prospectus supplement for primary offering
24 Feb 21
S-8
Registration of securities for employees
24 Nov 20
S-3
Shelf registration
9 Oct 20
S-8
Registration of securities for employees
27 Aug 20
15-12B
Securities registration termination
20 Jul 20
Proxies
DEF 14A
Definitive proxy
23 Apr 24
PRE 14A
Preliminary proxy
4 Apr 24
DEF 14A
Definitive proxy
14 Apr 23
PRE 14A
Preliminary proxy
3 Apr 23
DEF 14A
Definitive proxy
19 Oct 22
PRE 14A
Preliminary proxy
7 Oct 22
DEFA14A
Additional proxy soliciting materials
15 Dec 21
DEF 14A
Definitive proxy
9 Nov 21
PRE 14A
Preliminary proxy
29 Oct 21
DEFA14A
Additional proxy soliciting materials
4 Nov 20
Other
EFFECT
Notice of effectiveness
26 Apr 23
CORRESP
Correspondence with SEC
21 Apr 23
UPLOAD
Letter from SEC
18 Apr 23
UPLOAD
Letter from SEC
19 Mar 21
CORRESP
Correspondence with SEC
19 Feb 21
UPLOAD
Letter from SEC
10 Feb 21
EFFECT
Notice of effectiveness
19 Oct 20
CORRESP
Correspondence with SEC
15 Oct 20
UPLOAD
Letter from SEC
15 Oct 20
SEC STAFF ACTION
SEC staff action: Order
30 Sep 19
Ownership